Industry veterans Alexis Borisy and Zach Weinberg had plenty of reasons to celebrate their new venture’s first success story.
In November 2023, a small biotech called Forward Therapeutics became the first company to graduate from their startup accelerator, Curie.Bio. The accelerator had opened its doors less than a year prior, and this first launch was sign their program worked: Forward had come out the other side with enough promising data — and three drug candidates — to raise a $50 million Series A round. The biotech’s valuation had jumped five-fold between those financings, according to Weinberg. (Pitchbook now estimates the company is worth around $150 million.)
But Curie’s executives were left with a nagging question: Why hadn’t they invested in the Series A round? They knew the science, they knew the team, and — thanks to a provision in their earlier term sheet — they had a guaranteed spot in the financing round, if they wanted it. The only thing Curie didn’t have was the money.
Click this link for the original source of this article.
Author: Allison DeAngelis
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.